AR and prostate cancer: Darolutamide showed a strong affinity for the AR in these live prostate cancer cells, which confirms the strong AR binding previously measured in extracts from rat ventral prostates [38] and the potent inhibitory activity determined in cell-based transactivation assays for wild-type AR and different mutants, including H875Y, which is expressed in the androgen-dependent CWR22Pc-R1-AD1 model used here [16,38].